LCM
AXSM icon

Laurion Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Laurion Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Buy
+1,155
New +$250K 0.01% 365
2019
Q2 		– Sell
-219,000
Closed -$3.12M – 892
2019
Q1 		$3.12M Buy
+219,000
New +$2.03M 0.04% 267

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Laurion Capital Management's AXSM Position: Q2 2026 in Review

Laurion Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,155 shares worth $283K. The stake represents 0.01% of the portfolio and ranks #365 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in AXSM as recently as Q1 2019.

Laurion Capital Management first reported a position in AXSM in Q1 2019 and has held it in 2 quarters since. The position peaked at $3.12M in Q1 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Laurion Capital Management held 1,155 shares of Axsome Therapeutics worth $283K as of Q2 2026.
  • Axsome Therapeutics was a new Laurion Capital Management position in Q2 2026.
  • Axsome Therapeutics made up 0.01% of Laurion Capital Management's portfolio in Q2 2026, its #365 holding.
  • Laurion Capital Management first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 2 quarters since.
  • Laurion Capital Management's Axsome Therapeutics position peaked at $3.12M in Q1 2019.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.